Moolec Science Limited, a wholly owned subsidiary of Moolec Science SA (NASDAQ:MLEC), announced that it has achieved stable expression of bovine myoglobin in the seeds of the common pea (Pisum sativum). The breakthrough was the result of a 28‑month research partnership with a leading U.S. academic institution and represents the first time a plant‑based system has produced this key animal protein in a crop seed.
The achievement demonstrates the versatility of Moolec’s molecular‑farming platform. By engineering peas to produce bovine myoglobin, the company has expanded its crop base beyond safflower and soybean and has created a new pathway for plant‑based pork alternatives that more closely mimic the color, iron content and flavor profile of real pork. The research project’s duration underscores the company’s long‑term commitment to developing scalable, low‑cost protein solutions.
Moolec has already secured USDA approval for its genetically engineered pea, adding to its existing approvals for safflower and soybean. The company has outlined a commercialization timeline that targets a 2028 launch for its PEEA1 product line—genetically engineered peas producing bovine myoglobin—and a 2027 launch for its Piggy Sooy platform, which delivers pork proteins in soybeans.
"This is not just a scientific milestone; it is a clear signal of the scalability and versatility of our platform. Successfully expressing a heme protein in pea is a powerful validation of our ability to expand our technology across crops and product categories. This is how we build a pipeline, not just a product, and how we translate innovation into long‑term, scalable value for our shareholders," said Alejandro Antalich, CEO of Moolec Science.
"With USDA approval for our GE pea, Moolec has now secured regulatory clearance for all of our key crops in the US: safflower, soybean, and pea. We are proud to be the only Molecular Farming company with three US regulatory approvals and a major commercial contract. This milestone underscores our leadership in the landscape with tangible, science‑backed results," added Gastón Paladini, CEO and Co‑Founder of Moolec.
Investors responded positively to the announcement, citing the validation of Moolec’s platform and the potential for new revenue streams from plant‑based pork alternatives.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.